Previous 10 | Next 10 |
Investing in biotech stocks can seem like a speculative gamble on binary outcomes, sort of like buying lottery tickets. Fortunately, there are some mid-cap biotechs actually making a profit and that have development pipelines stocked with drug candidates that could produce big winners, giving pa...
Ionis Pharmaceuticals (NASDAQ: IONS ) and majority-owned affiliate Akcea Therapeutics (NASDAQ: AKCA ) initiate a Phase 3 clinical trial, CARDIO-TTRansform , evaluating cardiovascular (CV) outcomes in transthyretin-mediated amyloid cardiomyopathy (ATTR cardiomyopathy) patients receiving AK...
BOSTON and CARLSBAD, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the initiation of the CARDIO-TTRansform Phase 3 cardiovascular o...
Patients treated with AKCEA-APO(a)-L Rx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile Global Lp(a)HORIZON Phase 3 cardiovascular outcomes study underway BOSTON and CARLSBAD, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeu...
BOSTON and CARLSBAD, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that, following a strategic portfolio decision by Novartis not t...
The easing of trade tensions between the U.S. and China, plus word from the Federal Reserve that interest rates may not head higher in 2020, have helped large-cap stocks rally to 52-week highs. Mid-cap stocks have also performed well, but unlike the SPDR S&P 500 Trust ETF ( SPY ), whic...
BOSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the company as chief operating officer. In this role, Mr. Howarth will oversee a broad range of operatio...
Akcea Therapeutics (NASDAQ: AKCA ) and Ionis Pharmaceuticals (NASDAQ: IONS ) have initiated the NEURO-TTRansform Phase 3 clinical trial for AKCEA-TTR-L Rx in patients with polyneuropathy caused by h856ereditary TTR amyloidosis, or hATTR amyloidosis. More news on: Ionis Pharmaceuticals, ...
BOSTON and CARLSBAD, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced initiation of the NEURO-TTRansform Phase 3 clinical trial for AK...
Under Priority Review status, the FDA approves Alnylam Pharmaceuticals' ( ALNY +7.5% ) RNAi therapeutic givosiran, branded as Givlaari, for acute hepatic porphyria (AHP). More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Akcea Therapeutics, Inc., Healthcare st...
News, Short Squeeze, Breakout and More Instantly...
Akcea Therapeutics Inc. Company Name:
AKCA Stock Symbol:
NASDAQ Market:
Akcea Therapeutics Inc. Website:
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif. , Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, In...
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif. , Oct. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...